Reference priceEUR €158.40Original source price: INR 14,400.00. Converted estimates are available by currency selection.
| Brand | Bevacizumab BS Intravenous |
|---|---|
| Manufacturer | Daiichi Sankyo Esfa Co.Ltd. |
| Prescription required | Yes |
Bevacizumab BS Intravenous Infusion 400mg/16ml (Bevacizumab(Genetical Recombination))
Bevacizumab(Genetical Recombination)
Description
Bevacizumab BS Intravenous Infusion 400mg/16ml (Bevacizumab(Genetical Recombination)) is a medicine catalog record in the MediPriceHub database. Active ingredient: Bevacizumab(Genetical Recombination). Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Daiichi Sankyo Esfa Co.Ltd.. Therapeutic category: Medicine Library > Oncology Medicines > Colorectal Cancer Medicines. Pack information: 400, 1 x 16. Origin country or market: Japan. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).How to Use
Use Bevacizumab(Genetical Recombination) under the supervision of a qualified healthcare professional. It should be prepared and administered only by trained healthcare professionals in a setting appropriate for injectable or infusion medicines. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: Bevacizumab(Genetical Recombination). Pack size: 400, 1 x 16. Pack unit: bottle. Manufacturer: Daiichi Sankyo Esfa Co.Ltd.. Origin country: Japan. Source category: Medicine Library > Oncology Medicines > Colorectal Cancer Medicines. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
Cancer medicines may cause fatigue, nausea, vomiting, diarrhea or constipation, appetite changes, mouth sores, rash, changes in blood counts, infection risk, liver or kidney test changes, bleeding risk, neuropathy, infusion reactions, or organ-specific toxicity depending on the medicine. Injectable and infusion products may also cause administration-site pain, swelling, infection, infusion reactions, or hypersensitivity. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, confusion, serious bleeding, signs of infection, or rapidly worsening symptoms. The approved local prescribing information is the controlling source for the complete adverse-reaction profile.Diese Angaben dienen nur als Referenz. Lassen Sie sich vor der Anwendung eines Medikaments von medizinischem Fachpersonal beraten.